A string of blunders led to the value of Novo Nordisk dropping £52bn last week. Could a new weight-loss pill help it regain ...

Novo Nordisk faces a critical phase with its obesity drug Wegovy as it confronts competition from Eli Lilly and potential job ...

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...

The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.

Maziar Mike Doustdar, who was named as Novo Nordisk’s new CEO last week, spoke on a second quarter earnings call of ...

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...

Supreme Group said the deal deepens its expertise in rare disease and pharma and expands the creative and omnichannel ...

Super Micro, AMD, and Snap stocks tumbled after quarterly earnings reports. Arista and Disney stocks were rising.

Karsten Munk Knudsen, CFO of Novo Nordisk, discusses the prospect of tariffs on pharmaceuticals and the importance of the U.S ...

The shrinking ranks of "Dividend Knight" contenders. Healthcare stocks with hard times but high yields. What investors should ...

Even though Novo Nordisk warned that copycat versions of its obesity and diabetes drugs would hurt sales in the U.S., second-quarter sales saw a 67% rise year on year. More news covers telehealth ...

Novo Nordisk experiences heightened competition from copycat versions of its Wegovy obesity drug, affecting its market share, ...